Search
Bexotegrast
go.drugbank.com/drugs/DB16515InvestigationalIn addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713]. … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical
Dibekacin
go.drugbank.com/drugs/DB13270ApprovedDibekacin is an aminoglycoside antibiotic marketed in Japan [L5623].
Cilansetron
go.drugbank.com/drugs/DB04885ExperimentalCilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
Cixutumumab
go.drugbank.com/drugs/DB12250InvestigationalCixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types. … Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.
Ichthammol
go.drugbank.com/drugs/DB11341ApprovedIt is available in OTC products as an active ingredient for the treatment of skin disorders such as eczema, psoriasis and boils as it is thought to exhibit anti-inflammatory, antibacterial and antimycotic … It is an ammonium salt of dark sulfonated shale oil (bituminous schists) produced via distillation of the oil followed by sulfonation and neutralization.
Products: SCHWARZE SALBE 20% LICHT N, SCHWARZE SALBE 50% LICHT NMimopezil
go.drugbank.com/drugs/DB05520ExperimentalMimopezil is an acetylcholinesterase (AChE) inhibitor that has demonstrated potential use in the treatment of Alzheimer's disease. … Mimopezil is a pro-drug that is rapidly absorbed and converted into huperzine A.
Synonyms: N-(2-Hydroxy-3-methoxy-5-chlorobenzylidene)huperzine AOPC-28326
go.drugbank.com/drugs/DB05461ExperimentalIt is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome. … At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary
Binodenoson
go.drugbank.com/drugs/DB04853InvestigationalThis specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion … Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor.